December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity ↗
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
News headline image
What's Going On With Viking Therapeutics Stock On Wednesday? ↗
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
News headline image
My 5 Favorite Dirt Cheap Stocks to Buy Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
News headline image
Amgen Expands Development Plans For Highly Anticipated Obesity Drug ↗
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
News headline image
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts ↗
Via The Motley Fool
News headline image
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. ↗
Via The Motley Fool
News headline image
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks? ↗
Via The Motley Fool
Topics Government
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
1 Stock Down 34% This Year to Buy and Hold ↗
Via The Motley Fool
News headline image
Could Viking Therapeutics Become the Next Eli Lilly? ↗
Via The Motley Fool
News headline image
3 Best Growth Stocks to Buy in June ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Government
News headline image
Better Weight Loss Stock: Amgen or Viking Therapeutics? ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Bumped 3% Higher Today ↗
Via The Motley Fool
News headline image
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
News headline image
Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗
Via The Motley Fool
Topics Government
News headline image
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Down Nearly 20%: Should You Buy the Dip on Eli Lilly? ↗
Via The Motley Fool
Topics Earnings Government World Trade
News headline image
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Was Victorious This Week ↗
Via The Motley Fool
News headline image
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday ↗
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
News headline image
Is Novo Nordisk Stock a Buy? ↗
Via The Motley Fool
News headline image
Where Will Viking Therapeutics Be in 3 Years? ↗
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years. 
Via The Motley Fool
Topics Bankruptcy
News headline image
1 Beaten-Down Stock to Buy and Hold for 10 Years ↗
Via The Motley Fool
Topics Economy
News headline image
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? ↗
Via The Motley Fool
News headline image
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Popped Again Today ↗
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Popped Today ↗
2025 is the year we learn whether Viking Therapeutics stock will be a winner. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.